Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.

Huemer, F; Schlintl, V; Hecht, S; Hackl, H; Melchardt, T; Rinnerthaler, G; Greil, R; Weiss, L. Clin Colorectal Cancer. 2019 Jun;18(2):159-166.e3. doi: 10.1016/j.clcc.2019.04.003. Epub 2019 Apr 11.

Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).

Gampenrieder, SP; Peer, A; Weismann, C; Meissnitzer, M; Rinnerthaler, G; Webhof-er, J; Westphal, T; Riedmann, M; Meissnitzer, T; Egger, H; Klaassen Federspiel, F; Reitsamer, R; Hauser-Kronberger, C; Stering, K; Hergan, K; Mlineritsch, B; Greil, R. Breast Cancer Res. 2019 Jan 31;21(1):19. doi: 10.1186/s13058-018-1091-y.

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.

Huemer, F; Lang, D; Westphal, T; Gampenrieder, SP; Hutarew, G; Weiss, L; Hackl, H; Lamprecht, B; Rinnerthaler, G; Greil, R. J Clin Med. 2019 Jul 10;8(7):1014. doi: 10.3390/jcm8071014.

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Huemer, F; Melchardt, T; Jansko, B; Wahida, A; Jilg, S; Jost, PJ; Klieser, E; Katja, S; Magnes, T; Pleyer, L; Greil-Ressler, S; Rass, C; Greil, R; Egle, A. Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.

Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.

Egle, A; Melchardt, T; Obrtlíková, P; Smolej, L; Kozák, T; Steurer, M; Andel, J; Burgs-taller, S; Mikušková, E; Gercheva, L; Nösslinger, T; Papajík, T; Ladická, M; Girschiko-fsky, M; Hrubiško, M; Jäger, U; Voskova, D; Pecherstorfer, M; Králiková, E; Bur-coveanu, C; Spasov, E; Petzer, A; Mihaylov, G; Raynov, J; Oexle, H; Zabernigg, A; Flochová, E; Palášthy, S; Stehlíková, O; Doubek, M; Altenhofer, P; Weiss, L; Mag-nes, T; Pleyer, L; Klingler, A; Mayer, J; Greil, R. Cancer Med. 2019 Apr;8(4):1401-1405. doi: 10.1002/cam4.1980. Epub 2019 Mar 19.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by I-xazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

Ludwig, H; Poenisch, W; Knop, S; Egle, A; Schreder, M; Lechner, D; Hajek, R; Gun-silius, E; Krenosz, KJ; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenba-cher, W; Melchardt, T; Greil, R; Zojer, N. Br J Cancer. 2019 Oct;121(9):751-757. doi: 10.1038/s41416-019-0581-8. Epub 2019 Sep 27.

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematolo-gic toxicities: further results from the prospective PANTHER study with focus on obese patients.

Matikas, A; Foukakis, T; Moebus, V; Greil, R; Bengtsson, NO; Steger, GG; Untch, M; Johansson, H; Hellström, M; Malmström, P; Gnant, M; Loibl, S; Bergh, J. Ann Oncol. 2019 Jan 1;30(1):109-114. doi: 10.1093/annonc/mdy475.

Good Response of Lupus Hepatitis to Mycophenolate Mofetil and Belimumab as of Lupus Exanthema to Rituximab: A Case Report.

Psenak, O; Studnicka-Benke, A; Haufe, H; Greil, R. Rheumatology: Current Research. 2019; 9(1): 247-251.

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Leisch, M; Jansko, B; Zaborsky, N; Greil, R; Pleyer, L. Cancers (Basel). 2019 Feb 21;11(2):252. doi: 10.3390/cancers11020252.

Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.

Leisch, M; Egle, A; Greil, R. Future Oncol. 2019 Jan;15(2):109-120. doi: 10.2217/fon-2018-0492. Epub 2018 Aug 16.